Review of lamotrigine and its clinical applications in epilepsy

被引:37
作者
Choi, H [1 ]
Morrell, MJ [1 ]
机构
[1] Columbia Univ, Dept Neurol, New York, NY 10027 USA
关键词
antiepileptic; clinical efficacy; lamotrigine; serious drug-related rash;
D O I
10.1517/14656566.4.2.243
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lamotrigine is an anti-epileptic agent with broad efficacy. Lamotrigine works at voltage-sensitive sodium channels, thereby stabilising the neuronal membrane and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate. Early preclinical animal studies indicate its broad-spectrum efficacy, which was later confirmed in clinical trials. Multiple randomised, placebo-controlled and comparative trials demonstrate its efficacy against partial and secondarily generalised seizures. Open-label trials show its efficacy against generalised seizures, especially absence seizures of childhood absence epilepsy and generalised seizures of juvenile myoclonic epilepsy. Lamotrigine has a wide clinical dose range and possesses favourable pharmacokinetic properties. It has a good tolerability and safety profile, which enhance compliance. Its small risk of serious skin rash should be weighed against its potential benefits when choosing lamotrigine on an individual basis. Lamotrigine is an excellent therapeutic option in epilepsy.
引用
收藏
页码:243 / 251
页数:9
相关论文
共 57 条
[1]   LAMOTRIGINE FOR THE TREATMENT OF EPILEPSY IN CHILDHOOD [J].
BESAG, FMC ;
WALLACE, SJ ;
DULAC, O ;
ALVING, J ;
SPENCER, SC ;
HOSKING, G .
JOURNAL OF PEDIATRICS, 1995, 127 (06) :991-997
[2]   HUMAN SAFETY OF LAMOTRIGINE [J].
BETTS, T ;
GOODWIN, G ;
WITHERS, RM ;
YUEN, AWC .
EPILEPSIA, 1991, 32 :S17-S21
[3]   DOUBLE-BLIND CROSSOVER TRIAL OF LAMOTRIGINE (LAMICTAL) AS ADD-ON THERAPY IN INTRACTABLE EPILEPSY [J].
BINNIE, CD ;
DEBETS, RMC ;
ENGELSMAN, M ;
MEIJER, JWA ;
MEINARDI, H ;
OVERWEG, J ;
PECK, AW ;
VANWIERINGEN, A ;
YUEN, WC .
EPILEPSY RESEARCH, 1989, 4 (03) :222-229
[4]  
Biraben A, 2000, NEUROLOGY, V55, P1758
[5]   Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy [J].
Biton, V ;
Mirza, W ;
Montouris, G ;
Vuong, A ;
Hammer, AE ;
Barrett, PS .
NEUROLOGY, 2001, 56 (02) :172-177
[6]  
BOAS J, 1995, EPILEPSIA, V36, pS113
[7]   DOUBLE-BLIND COMPARISON OF LAMOTRIGINE AND CARBAMAZEPINE IN NEWLY-DIAGNOSED EPILEPSY [J].
BRODIE, MJ ;
RICHENS, A ;
YUEN, AWC .
LANCET, 1995, 345 (8948) :476-479
[8]  
Brodie MJ, 2000, Epilepsia, V41, P138
[9]   LONG-TERM OBSERVATIONS ON THE CLINICAL USE OF LAMOTRIGINE AS ADD-ON DRUG IN PATIENTS WITH EPILEPSY [J].
COCITO, L ;
MAFFINI, M ;
LOEB, C .
EPILEPSY RESEARCH, 1994, 19 (02) :123-127
[10]   KINETIC EFFECTS OF MULTIPLE ORAL DOSES OF ACETAMINOPHEN ON A SINGLE ORAL DOSE OF LAMOTRIGINE [J].
DEPOT, M ;
POWELL, JR ;
MESSENHEIMER, JA ;
CLOUTIER, G ;
DALTON, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :346-355